AMRNAmarin Corporation plc

$335M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$135M+34.3% YoY

Gross Profit

$107M78.7% margin

Operating Income

$4M3.1% margin

Net Income

$4M3.3% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

-12.7%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$2M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$915M

Total Liabilities

$312M

Stockholders' Equity

$603M

Cash & Equivalents

$214M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$135M	$101M	+34.3%
Gross Profit	$107M	$78M	+36.5%
Operating Income	$4M	-$3M	+265.3%
Net Income	$4M	-$2M	+342.6%

Revenue Segments

Product

$134M99%

Licensing And Royalty

$2M1%

AMRN Q2 2020 Earnings — Amarin Corporation plc Revenue & Financial Results | Market Cap Arena